Table 1.
Clinical, Endoscopic, and Laboratory Features of 80 IBD Patients Undergoing Colonoscopy at the University of Alberta Inflammatory Bowel Disease Clinic.
| Crohn's Disease | Ulcerative Colitis | |
|---|---|---|
| n (%) | 40 (50.0) | 40 (50.0) |
| Male (%) | 17 (42.5) | 15 (37.5) |
| Disease Extent (%) | — | — |
| Ileal | 20 (50.0) | — |
| Ileocolonic | 13 (32.5) | — |
| Colonic | 7 (17.5) | — |
| Proctitis | — | 3 (7.5) |
| Left-sided | — | 13 (32.5) |
| Pancolitis | — | 24 (60.0) |
| Active IBD Treatment (%) | — | — |
| Steroids | 1 (2.5) | 1 (2.5) |
| Biologics | 15 (37.5) | 8 (20.0) |
| Immunomodulators | 15 (37.5) | 14 (35.0) |
| Endoscopic MH | 26 (65.0) | 24 (60.0) |
| Biomarkers (median, IQR) | — | — |
| FCP (μg/g) | 330 (215–599) | 322 (199–607) |
| FIT (ng/mL) | 81 (15–1000) | 421 (30–1000) |
| Sensitivity for MH | — | — |
| FCP < 150 μg/g | 1.00 | 0.94 |
| FIT < 50 μg/mL | 0.57 | 0.81 |